A hub is a coordination point that manages patient access to a specialty or high-cost therapy from the moment a prescription is written until the patient starts and continues treatment. It handles benefit verification, prior authorization support, financial assistance enrollment, and ongoing adherence outreach. Most hubs also coordinate with specialty pharmacies, payers, and the prescriber's office to keep a patient moving forward when insurance requirements or affordability issues threaten to stall treatment. The scope can vary by manufacturer and therapy, but the core job is the same: reduce the friction between a prescription and a patient receiving their medication.

A specialty pharmacy dispenses medication. A hub manages everything that happens before and around that dispensing event. Where a specialty pharmacy focuses on fulfillment, shipping, and clinical support tied to the drug itself, a hub focuses on access barriers: verifying coverage, securing prior authorization, connecting patients to copay or foundation assistance, and tracking the status of a case across multiple parties. Many programs use both. The specialty pharmacy fills the prescription once access is confirmed, while the hub handles getting the case to that point and keeping it there through renewals and reauthorizations.

Hub programs can be built around the specific requirements of a limited-distribution drug or a new specialty launch. A therapy with a narrow prescriber base, complex REMS requirements, or an unusual payer landscape needs workflows suited to that reality rather than a generic template. Customization typically shows up in case manager training, the sequencing of benefit verification and prior authorization steps, the criteria used to flag at-risk cases, and how tightly the hub coordinates with a limited network of specialty pharmacies. A launch brand in particular benefits from a hub structure that can adapt quickly as early real-world data reveals where patients are getting stuck.

Patient support programs tend to break down at the handoff points, not within any single step. A benefit verification might go smoothly, and a prior authorization might get approved, but if the result doesn't reach the prescriber's office quickly, or if a patient doesn't hear back during the wait, the case stalls anyway. Case managers are often measured in volume rather than outcomes, which can leave complex cases without enough attention. Add in inconsistent documentation, payer requirements that change without notice, and limited visibility into where a case stands, and small gaps compound into patients who quietly fall out of the program before ever starting treatment.

Speed-to-start suffers because specialty access involves several independent parties working in sequence rather than in parallel. A prescriber submits a request, a payer reviews it, a hub coordinates the paperwork, and a specialty pharmacy waits to fill it once everything clears. Each handoff introduces a delay, and none of these parties has full visibility into what the others are doing. Prior authorization alone can take days or weeks, and if a denial requires an appeal, the timeline extends further. Most hub reports show that a case is delayed but stop short of explaining which step caused it, which makes the underlying bottlenecks hard to fix even when everyone involved is trying to move quickly.

Prior authorization is the process by which a health insurer requires approval before it covers a specific medication, procedure, or service. Before a pharmacy can dispense a drug or a patient can begin treatment, the prescribing provider must submit documentation to the payer justifying medical necessity, and the payer must review and approve that request before coverage kicks in.

For specialty drugs, prior authorization carries outsized weight for a few reasons.

Specialty medications tend to treat complex, chronic, or rare conditions, and they often come with high price tags, sometimes tens or hundreds of thousands of dollars annually. Payers use prior authorization as a cost control mechanism, so the bar for approval is typically higher than it is for standard medications. The documentation requirements are more extensive, and the criteria for medical necessity are often narrower.

The process also tends to be slower and less standardized than for traditional drugs. Requirements vary by payer, by plan, and sometimes even by region within the same payer, so what qualifies as sufficient documentation for one insurer might fall short for another. That variability creates delays, and delays matter enormously in specialty and rare disease treatment, where a patient's condition can progress while they wait for approval.

This is precisely why prior authorization sits at the center of hub services and patient access programs. A hub's ability to navigate payer-specific requirements accurately and quickly has a direct effect on how fast a patient starts therapy, and a poorly managed prior authorization process can undo the value of an otherwise strong treatment plan before a patient ever receives their first dose.

A field reimbursement manager, or FRM, is a role within a pharmaceutical company's patient access team that works directly with healthcare provider offices to resolve coverage and reimbursement issues for a specific drug or portfolio.

FRMs typically operate in the field, meaning they visit or maintain ongoing relationships with physician practices, infusion centers, and specialty pharmacies in an assigned territory. Their core function is to help provider staff navigate the administrative side of getting a patient onto therapy: understanding a specific payer's prior authorization requirements, troubleshooting claim denials, explaining benefit investigation results, and connecting practices to manufacturer support programs like copay assistance or patient assistance programs.

The role sits at an important intersection. Provider offices often lack the staff time or specialized knowledge to manage the reimbursement complexity of specialty drugs, particularly when a single practice might treat patients across dozens of different payers, each with its own rules. An FRM brings payer-specific expertise directly to the point of care, which can meaningfully reduce the time between a prescription being written and a patient starting treatment.

FRMs are typically non-clinical and are legally restricted from discussing product efficacy, safety, or clinical decision-making, since that falls under the purview of clinical sales representatives. Their value is entirely operational: making sure coverage and access barriers do not stand between a patient and a therapy their doctor has already decided is appropriate.

Given how central this role is to the access journey, an FRM's effectiveness often depends on the same kind of data quality and process rigor that gets discussed in hub vendor evaluations. When benefit verification and prior authorization processes are unreliable, FRMs end up spending more time troubleshooting and less time accelerating access for patients.

“Time to therapy” refers to the total elapsed time between a healthcare provider deciding whether a patient should start a specific medication and the patient actually receiving their first dose.

It's a metric that spans the entire access journey rather than any single step. That journey typically includes benefit verification, prior authorization submission and approval, specialty pharmacy or distribution logistics, and any financial assistance enrollment the patient might need before therapy can begin. A delay at any point along that chain extends the overall time to therapy, even if every other step moves quickly.

The metric matters most in specialty and rare disease treatment, where conditions are often progressive or acutely symptomatic. A patient waiting weeks for a prior authorization decision on oncology or rare disease therapy is not simply experiencing an administrative inconvenience. That delay can translate into disease progression, increased hospitalization risk, or a narrower window in which the treatment is effective at all.

Time to therapy has also become a standard benchmark that hub vendors and patient support programs use to measure their own performance, and it's a metric that brands increasingly hold vendors accountable to. That's part of why it comes up so often in vendor evaluation conversations. A vendor might report a strong average time to therapy while masking wide variability underneath, where some patients move quickly, and others get stuck for weeks. Understanding what sits behind the headline number, rather than the number alone, is often what separates a program that's actually working from one that just looks good in a pitch deck.